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ABSTRACT 
Mahreed Rahman Khan 
DO OBESE INDIVIDUALS HAVE LESS CROSS-REACTIVE, NON-NEUTRALIZING 
ANTIBODIES TO THE 2009 PANDEMIC H1N1 INFLUENZA VIRUS? 
 (Under the direction of Melinda A. Beck) 
 
Background: Obesity has recently become a major global health concern as the worldwide 
population of those who are obese has increased to over 1 billion overweight adults. Recent studies 
suggest that obesity is a risk factor for severity of influenza virus, especially during the 2009 
pandemic H1N1 outbreak. During the 2009 influenza pandemic, it was found that while overall 
severity to pH1N1 was mild, obese individuals had higher rates of hospitalization and severity than 
healthy weight individuals. The mechanism for impaired immunity in obese individuals will be 
explored.  
Objective: To determine if naïve obese individuals have less pre-existing cross-reactive, non-
neutralizing antibodies to pH1N1 proteins NP, M1 and HA than healthy weight individuals.  
Results: The average M1 antibody OD value in healthy weight patients was found to be 1.12 while 
average OD value in obese patients was found to be 1.01. The average NP antibody OD value in 
healthy weight patients was found to be 0.91 while the average antibody OD value in obese patients 
was found to be 0.97. The average HA antibody OD for healthy weight patients was 1.32 while 
the average antibody OD value for obese patients was 1.28. None of these differences were 
significant. 
Conclusion: Obese individuals had similar levels of pre-existing, non-neutralizing, cross-reactive 
antibodies to pH1N1 compared with healthy weight individuals. Mechanism for impaired 
immunity in obese individuals likely lies elsewhere.  
~ 3 ~ 
 
ACKNOLWEDGMENTS  
I would like to thank my mentors Dr. Melinda Beck and Justin Milner for 
guiding me throughout this project and helping me meet deadlines. I would like to 
thank all of Beck lab for their support and assistance with this project. I would also 
like to thank my parents for their unconditional support throughout all of my 
schooling.  
 
 
 
 
 
“If you learn from defeat, you have never truly lost”  
–Zig Ziglar 
 
 
 
 
~ 4 ~ 
 
TABLE OF CONTENTS 
LIST OF TABLES………………………………………………………………………...5 
LIST OF FIGURES…………………………………………………….............................6 
CHAPTERS 
1. STUDY AIMS AND HYPOTHESIS………………………………………....8 
2. INTRODUCTION…………………………………………………………...10 
2.1 Obesity……………………………………………………………….10 
2.2 Obesity and immune response……………………………………….11 
2.3 Influenza Virus and Infection………………………………………..12 
2.4 Influenza Vaccination………………………………………………..15 
2.5 Pandemic H1N1 outbreak……………………………………………16 
2.6 Cross reactive immunity to Influenza Infection……………………...17 
  3. METHODS……………………………………………………………………19 
   3.1 Study Design and Participants……………………………………….19 
   3.2 Indirect ELISA…………………………………………….…………19 
   3.3 Statistical Analysis……………………………………………...……21 
  4. RESULTS………………………………………………………………..……22 
   4.1 Demographics of the Study Population…………………………...…22 
   4.2 Inf/Ped cross reactive antibody response………………………….…24 
   4.3 Healthy Weight and Obese antibody response…………………...….26 
  5. DISCUSSION………………………………………………………..………..30 
   5.1 Cross reactive antibodies to influenza………………………...……..30 
   5.2 Limitations…………………………………………………….……..31 
   5.3 Future studies………………………………………………….……..32 
 REFERENCES……………………………………………………………………..……34 
 
 
~ 5 ~ 
 
LIST OF TABLES 
1. Weight classifications and respective BMI ranges...................................................... 10 
2. Influenza extracellular and intracellular proteins with percentage conserved 
between different influenza strains………………………………………………….. 
 
14 
3. Concentration of pH1N1 protein plated with respective serum dilution series……... 21 
4. Demographic summary of BMI, age, gender and race in subject population……….. 22 
5. Mean OD and SE for HA, M1, NP in Healthy Weight and Obese subjects………… 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 6 ~ 
 
 
LIST OF FIGURES 
1. Results of HAI for pre/post-vaccine in Healthy Weight and Obese patients…………. 24 
2. M1 OD values for serial dilution series in infected and pediatric samples…………… 25 
3. NP OD values for serial dilution series in infected and pediatric samples……………. 25 
4. HA OD values for serial dilution series in infected and pediatric samples…………… 26 
5. M1 mean antibody OD value at a 1:3000 dilution factor…………………….……….. 27 
6. NP mean antibody OD value at a 1:750 dilution factor…………………..…………... 28 
7. HA mean antibody OD value at a 1:27000 dilution factor……………………………. 29 
 
 
 
 
 
 
 
 
 
 
 
~ 7 ~ 
 
LIST OF ABBREVIATIONS 
pH1N1 Pandemic H1N1 
CDC Center of Disease Control 
WHO World Health Organization 
BMI  Body Mass Index 
NP Nucleoprotein 
M1 Matrix Protein 1 
HA Hemagglutinin 
HRP Horse Radish Peroxidase 
HW Healthy Weight 
OB Obese 
OD Absorbance  
ELISA Enzyme-linked immunoabsorbent assay 
HAI Hemagglutinin inhibition test 
TIV Trivalent influenza vaccine 
LAIV Live attenuated influenza vaccine 
 
 
 
 
 
 
~ 8 ~ 
 
CHAPTER 1 
STUDY AIMS AND HYPOTHESIS 
 Obesity has recently become a major global health concern as the worldwide population of 
those who are obese has increased to over 1 billion overweight adults, and nearly two-thirds of the 
US population has been reported as overweight or obese.1 Obesity is a topic of concern because of 
the associated risk factors, which include diabetes mellitus, dyslipidemia, hypertension, 
osteoarthritis, metabolic syndrome disease, and cardiovascular disease. In addition, obesity is 
considered an immune-compromising condition.1,7 The classification of obesity is determined by 
body mass index (BMI).2 The Center of Disease Control (CDC) calculates BMI via height (m) and 
weight (kg) measurements, the formula: weight (kg)/ [height (m)]2.2  
 The influenza virus is a contagious respiratory illness that is routinely spread among 
humans.3 The virus ranges in severity, from mild to severe illness which can result in 
hospitalization and even death. According to the World Health Organization (WHO), it is 
estimated that up to 5 million cases of severe illness occur along with 250,000 to 500,000 deaths 
worldwide.4 While most people recover within two weeks without serious medical treatment, those 
who are immunocompromised (such as obese individuals) are more prone to severe 
complications.4 In the US, the CDC estimates that each year there are between 3,000 to 49,000 
influenza related deaths. The most effective prevention method for influenza infection is via annual 
vaccination.5 Vaccines contain weakened or attenuated (dead) antigens which are not strong 
enough to actually cause the disease, but do initiate immune response. The immune system 
produces antibodies against the antigen, producing memory cells that prevent re-infection when 
the disease is encountered in the future.9 
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 Recent studies suggest that obesity is a risk factor for severity of influenza virus, especially 
during the 2009 pandemic H1N1 outbreak.6 While obesity does induce a pro-inflammatory state 
in the human body, the exactly immunological consequences of obesity on the immune response 
to influenza infection are not specifically identified.7 Using an animal model, studies in our lab 
have demonstrated that obese mice have less cross-reactive antibodies to pH1N1 compared with 
lean mice. Cross-reactivity is measured by the way in which the body’s immune system can combat 
antigens which appear similar.21 It is likely the increased severity seen in obese humans to pH1N1 
was a result of decreased cross-reactive antibodies to the pandemic strain.36  
 
Specific Aim: To determine if naïve obese individuals have less pre-existing cross-reactive, non-
neutralizing antibodies to pH1N1 than healthy weight individuals. 
Hypothesis: Naïve Obese individuals will have less pre-existing cross-reactive antibodies to 
pH1N1 as compared to healthy weight individuals. Specifically, the antibody response to 
intracellular conserved protein of the flu virus matrix protein 1 (M1) and nucleoprotein (NP) will 
be lower in the obese compared with the naïve healthy weight individuals. The titer for obese 
individuals will be on average lower than the titer for healthy weight individuals for both conserved 
intracellular proteins of the influenza virus.  
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CHAPTER 2 
INTRODUCTION 
2.1 Obesity  
 The worldwide epidemic of obesity has more than doubled since 1980. It was reported in 
2008 that there were 1.4 billion overweight adults over the age of 20 around the world. More than 
35% of adults aged 20 and over are overweight, and 40 million children under the age of 5 were 
reported as overweight in 2011.1 Obesity is defined by a body mass index (BMI) of over 30. BMI 
is calculated by correlating height and weight to determine relative fat accumulation that may 
impair health. The Center of Disease Control (CDC) calculates BMI via height (m) and weight 
(kg) measurements (formula: weight (kg)/ [height (m)]2).2 BMI is one of the best methods for 
assessment of obesity and overweightness. The CDC defines four distinct categories of BMI: a 
BMI of < 18.5 indicates Underweight health status, BMI of 18.5-24.9 indicates Healthy weight or 
Normal, BMI of 25.0-29.9 indicates Overweight while a BMI of 30.0 and over indicates Obese.2 
Table 1 summarizes these classifications. 
 
 
 
 
 
Table 1. Weight classifications and respective BMI ranges 
   
WEIGHT CLASSIFICATION BMI 
Underweight Below 18.5 
Normal/Healthy Weight 18.5-24.9 
Overweight 25.0-29.9 
Obese 30.0 and greater 
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 Being overweight and obese have been cited as the fifth leading cause of global deaths.1 In 
addition to mortality rates, obesity has been linked to risk factors for stroke, cardiovascular disease, 
type 2 diabetes, hypertension, cancer, osteoarthritis and dyslipidemia. Obesity is one of the most 
preventable diseases as exercise and proper dieting can help lower BMI to a healthy range.26 In 
addition medical care costs for those who are obese in the US alone exceeded 147 billion dollars.27 
 Fundamentally, BMI exceeding 25 is generally caused by an energy imbalance, where 
more calories are consumed than expended.2 An increasing global trend is the consumption of fast 
foods or energy dense foods that are high in fat. In addition the rise in sedentary day jobs with 
limited physical activity and increasing sedentary modes of transportation has resulted in poor 
health among most populations. The combination of poor physical activity and increasing caloric 
consumption has resulted in the global obesity epidemic.1,2 Current trends suggest that by the year 
2030 more than 51% of the world population will be obese, a 33% increase in prevalence. 
Additionally 549.5 billion more dollars will be used on medical costs resulting in more problems 
for healthcare cost containment.1  
 
2.2 Obesity and Immune Response 
 Immune dysfunction has been a recently cited associative health condition with obesity. 
How the immune system is affected by obesity is still relatively unknown as research has been 
limited. Current research suggests that obesity can be characterized as a low-grade, chronic 
inflammatory state which alters levels of metabolic hormones and circulating nutrients.30 The 
influence the pro-inflammatory state has on the immune system in obese individuals is still largely 
unexplored. Additional studies suggest that obesity increases the risk for nosocomial infections; 
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furthermore obesity has recently been isolated as an independent risk factor for increased 
morbidity for pandemic H1N1 virus.32 
 It has been reported that obese individuals are more prone to infection than lean subjects. 
Obese individuals have been shown to be more susceptible to infections, bacteremia and poor 
wound healing.30 Obesity, which can be considered a state of malnutrition, has also been known 
to affect both cell-mediated immune response and leucocyte count. Associated production of leptin 
and reduction of adiponectin affects the stimulation and activation of innate and adaptive immune 
response. Specific cytokine-like signaling pathways appear to be hindered with altered leptin 
levels. Other pathways which are affected include altered number of T-lymphocyte and B-cell 
synthesis and circulation, decreased dendritic cell function and decreased response to antigen 
stimulation.29 Moreover, obesity results in a pro-inflammatory state associated with increased 
levels of circulating pro-inflammatory proteins, in both obese children and adults.29,31   
 
2.3 Influenza Virus and Infection 
 Human influenza is a virus which has three separate strains, A, B and C. Influenza A and 
B are the only strains which are known to cause seasonal epidemics in humans. In addition 
Influenza A can be hosted in avian birds, humans and other mammals.8 Influenza is a respiratory 
infection which is transmitted through unprotected coughing and sneezing. Crowded and enclosed 
spaces harbor the virus, as well as hand contamination and direct inoculation.10 The influenza virus 
attaches to sialic acid receptors on the apical surface of human tracheal epithelial cells.33 Upon 
infection the body generally takes 1-4 days to begin responding to the virus and then works to 
combat it; during this time humans are most contagious.10 Severity of the infection ranges from 
asymptomatic to severe and even fatal outcomes. General symptoms include coughing, chills, 
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fever and headache. More complicated cases include development of pneumonitis, bacterial 
pneumonia and others. Generally, recovery from the infection occurs within 1 or 2 weeks, but 
sometimes the virus takes a more fatal tone. It is estimated that worldwide 5-10% of adults are 
infected annually with influenza, while 20-30% of children are infected. In addition anywhere 
from 3,000 – 49,000 deaths worldwide are attributed to the influenza virus.10 
  Influenza generally results in an immune response in populations that doesn’t result in 
hospitalization unless the person is in some way immunocompromised. Generally speaking those 
who are most susceptible to influenza infection include children, the elderly, those with chronic 
disorders (CVD, asthma, hypertension, diabetes), pregnant women, and those who are obese.11 In 
addition influenza is more commonly seen in large, crowded population centers such as large cities 
as the virus can move quickly while airborne and person to person contact is increased.  
  The influenza virus is a single-stranded RNA virus with a segmented genome that codes 
for specific proteins.12 The subtypes of influenza are determined by the glycoproteins which are 
expressed on the virus’s surface. Two specific glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA) are the receptors and binding sites for the virus. Mutations in the genes that 
code for these glycoproteins results in altered HA and NA proteins that results in the need for new 
vaccinations each year. In addition to the surface proteins, the virus contains many internal proteins 
as well. Matrix protein 1 (M1), a highly conserved protein among strains of flu gives strength and 
rigidity to the lipid envelope of the flu.12 RNA segments found within the virion of the virus are 
known as PB1 and PB2 and code for specific proteins. Nucleoprotein (NP), another highly 
conserved protein of the flu, is a structural protein. Many of the proteins of the flu virus and how 
conserved they are among different influenza strains are reported in Table 2.13 
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Table 2. Influenza extracellular and intracellular proteins with percentage conserved   
between different influenza strains. 
Upon exposure to the influenza virus, the virus binds to surface epithelial cells of the 
respiratory system. Glycoprotein HA has multiple sialic binding sites, making it a prime receptor 
for host cells (erythrocytes and surface epithelium). The virus is then endocytosed into the host 
cell and transcription of viral mRNA occurs.14 The body, upon detection of viral infection by RIG-
1 (recognizes viral infections) will initiate innate and adaptive immune responses through 
production of pro-inflammatory cytokines IFN alpha and beta. Next, respiratory dendritic cells 
(RDC’s) capture the viral antigen, present it on MHC-II and migrate towards lymph nodes. In the 
lymph nodes, RDC’s interact with naïve T and B cells, stimulating white blood cells producing 
plasma and memory cells, helping the body fight infection.15 Antibodies are created for 
Influenza Protein Percent Conserved between strains (%) 
Hemagglutinin (HA) 12 
Neuraminidase (NA) 17 
Matrix Protein 1 (M1) 57 
Nuceloprotein (NP) 56 
Ion channel (M2) 13 
PB1 74 
PB2 40 
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glycoprotein HA on the surface of the flu virus, preventing binding of the virus to host cells in the 
body. Additional antibodies are produced to other proteins of the virus.  
2.4 Influenza Vaccination  
 The severity of the flu virus has resulted in recommended protection from the infection 
through vaccination. The most effective way to prevent infection is to get vaccinated every year. 
The CDC recommends that everyone 6 months and older should receive a flu shot yearly.17 This 
is especially true for high risk patients such as the elderly, children, pregnant women and the 
immunocompromised.17 Due to the constantly changing nature of the influenza virus, antibodies 
from previous viruses are not as effective and may not result in proper protection against the 
current virus. The seasonal flu vaccine consists of two influenza type A strains and one influenza 
type B strain based on research and predictions of the circulating strain that season. In 2013 the 
very first quadravalent vaccine was distributed, consisting of two A viruses and two B viruses.  
Two types of administration are provided for the flu vaccine, trivalent inactivated influenza 
vaccine (TIV) and live attenuated influenza vaccine (LAIV). LAIV is a nasal spray which has 
weakened, but still live influenza virus which will more closely resemble normal infection.16 TIV 
is more common as it is the inactive virus administered subcutaneously or intramuscularly via 
needle. Vaccination has been reported to prevent anywhere from 70% to 90% of influenza-related 
illness in those who are healthy, and nearly 60% in older adults (over the age of 65).17 Vaccines 
contain weakened or attenuated (dead) antigens which are not strong enough to actually cause the 
disease, but do initiate immune response. The immune system produces antibodies against the 
antigen, producing memory cells that prevent re-infection when the disease is encountered in the 
future.10  
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2.5 2009 Pandemic H1N1 Outbreak  
 During the 2009-2010 flu season, the influenza strain H1N1 was identified in the US.16 
This virus is often referred to as the “swine flu” because many of the genes seen in the virus were 
similar to influenza found regularly occurring in US swine (pigs). Further research suggested that 
two more genes of the H1N1 were from avian and swine genes of European and Asian descent, 
making the virus a “quadruple reassortant”. The nature of this quadruple re-assortment resulted in 
a new influenza virus which had not been seen in over 40 years.16 Scientists and physicians were 
concerned because there would be no pre-existing immunity to a new strain such as H1N1, thus 
resulting in increased severity across all demographics.17 The novel strain of influenza A (pH1N1) 
is genetically distinct from any previous seasonal influenza virus, thereby rendering antibodies 
from previous seasons non-protective.19 
  During the subsequent flu season of the pandemic, the CDC reported the virus peaked 
from October to March and spread relatively quickly as compared to other flu seasons.18 However 
as the flu season continued, Dr. Jhung, of the CDC’s flu division told CNN that the spread and 
severity of the disease was typical of an influenza season.18 The CDC estimated that between 
188,000 to 381,000 US citizens were hospitalized due to the pandemic, not stemming from the 
average of 250,000-500,000 annually. In addition the estimated death toll of the pandemic ranged 
from 8,520 to 17,620.20 Both the number of infected and the death toll did not spike as highly as 
was expected from a new strain of flu. The relatively mild effects overall could be attributed to 
increased rate of vaccination and possibility of cross-reactive immunity from previous influenza 
strains. 
It was found, however, that the pandemic did affect those at higher risk more so than 
previous flu seasons. The obese, immunocompromised, young and pregnant faced much worse 
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outcomes than healthy adults. It was found that elderly had greater protectively to pH1N1, which 
is uncommon for any flu strain. It is likely that older adults had been exposed to a flu strain similar 
to pH1N1 during the first half of the 20th century.26 This likely resulted in higher affinity antibodies 
in older adults which prevented severity from pH1N1. The increase in hospitalization and mortality 
were alarming and drew reason for concern in at risk populations, especially the obese and 
immunocompromised. 
 
2.6 Cross Reactive Immunity 
 Cross-reactivity is measured by the way in which the body’s immune system can combat 
antigens which appear similar.21 Antibody binding sites, also known as epitopes, consist of about 
15 amino acid sequences, 5 of them being responsible for binding of the antibody. The paratope, 
which is the part of the antibody molecule that binds to the epitope, consists of about 50 variable 
amino acids. A paratope can bind to unrelated epitopes, and an epitope can bind to unrelated 
paratopes.21 Similar structures such as shape and charge can aid in unrelated paratopes and epitopes 
binding together. This relationship is the basis for cross reactive antibody immunity. 
 Concerning the influenza virus, the determination of epitopes which are presented on the 
virus’s surface is determined by the hemagluttanin and neuraminidase variation presented. H3N1 
and H3N2 have similar hemagluttanin epitopes while the neuraminidase antigen is different. It is 
likely that the antibody paratope to N1 can bind and provide protection against the N2 epitopes 
presented in the differing strain. As mentioned in the previous section, pandemic H1N1 was 
expected to have no cross reacting antibodies as the epitopes on pH1N1 were completely new to 
the majority of the population.  However, it soon became apparent that older individuals had cross-
reacting antibodies from exposures to pH1N1 like viruses, and therefore had pre-existing cross-
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reacting antibodies that could protect them from pH1N1 infection as opposed to younger 
individuals, who did not have cross-reacting antibodies.25 
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CHAPTER 3 
METHODS 
3.1 Study Design and Participants  
 Participants were recruited as part of a prospective observational study from the University 
of North Carolina Family Medicine Center in Chapel Hill, NC. The study is designed to understand 
the relationship between high BMI and immune response to the influenza TIV vaccine. For this 
study, participants were selected from adults who received the influenza vaccine during the 2010-
2011 flu season, the vaccine did not contain pH1N1 as one of the vaccine strains. 
 During the enrollment visit, the study nurse obtained informed consent, medical records, 
weight, height, BMI and baseline blood samples. For this study, a sample of 91 participants were 
selected, 45 obese individuals (BMI ≥30) and 46 healthy weight individuals (BMI 18.5-25). 
Participants selected were HAI negative. 
  
3.2 Indirect ELISA  
 In order to determine antibody levels to specific proteins of the influenza virus, enzyme-
linked immunoabsorbant assay (ELISA) was utilized. ELISA is useful in detecting the presence of 
a substance, generally an antigen or antibody. For accurate quantitative results, Indirect ELISA 
was used for this experiment.23 First, the antigen is plated in each respective well. Next blocking 
buffer is added to inhibit binding of antibody to open protein-binding sites. After incubation a 
primary antibody is added and after an addition incubation, secondary antibody-horse radish 
peroxidase (HRP) conjugate is added to bind to the primary antibody. Finally, a substrate such as 
tetramethylbenzidine (TMB) and peroxide is added. Any HRP bound to the secondary antibody 
will act on the TMB and peroxide to produce a blue byproduct. After a specified amount of time, 
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the reaction is stopped with the addition of sulfuric acid. The color intensity is proportional to the 
amount of HRP activity, which in turn is related to the bound antibody. The color intensity was 
measured at 450nm using a spectrophotometer.24  
Following the indirect ELISA protocol, first Hemagluttanin (HA), Matrix Protein 1 (M1) 
and Nucleoprotein (NP) from the 2009 pH1N1 were isolated, diluted with coating buffer (250 mL 
1x PBS solution with .397 NaCO3 and .935 HCO3) and 50 uL were platted to the 96 well plate. 
HA was concentrated to a 1:1 viral antigen to coating buffer ratio while M1 and NP were 
concentrated at a 3:1 viral antigen to coating buffer ratio. After a 20-30 hour incubation period at 
4ºc, the plates were flicked to remove any remaining antigen solution in wells and then blocked 
with 200 uL of blocking buffer (3 g dried milk with 100 mL coating buffer) for 1-3 hours at 36ºc. 
After blocking, plates were washed 6x with 10x PBS tween and then loaded with serum, diluted 
with loading buffer (3 g dried milk with 100 mL 1x PBS). Respective dilutions for each antigen 
are listed in Table 3. Respective dilution series selected were optimal for avoiding oversaturation 
of the serum to protein. ELISA plates with serum dilutions were again incubated for 20-30 hours 
at 4ºc. Following incubation, plates were again washed 6x with 10x PBS tween, then 50 uL of 
secondary antibody IgGt-HRP with loading buffer at a 1uL to 1mL ratio was added to each well. 
This was incubated at 36ºc for 1 hours. After incubation the plates were washed 6x with 10x PBS 
tween and then 100 uL of substrate, TMB solution, was added and let sit for 20 minutes at room 
temperature in a dark environment. Following 20 minutes, 100 uL 1 M sulfuric acid was added to 
each well for desired color change and absorbance readings. The Dynatech Elisa plate reader was 
used to read each ELISA plate at 450 nm for absorbance values.  
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pH1N1 Protein Concentration Serial dilution series  
Hemagglutinin (HA) 1 uL/mL 1:9000 
1:27000 
1:54000 
1:162000 
Matrix Protein 1 (M1) 3 uL/mL 1:3000 
1:9000 
1:27000 
1:54000 
Nucleoprotein (NP) 3 uL/mL 1:750  
1:3000 
1:9000 
1:27000 
Table 3. Concentration of pH1N1 protein plated with respective serum dilution series  
3.3 Statistical Analysis 
 End-point ELISA with subsequent O.D readings were used to analyze individual samples. 
Excel sheets with average of triplicate concentration readings of for each sample and respective 
protein were plotted. J.M.P Pro 9.0.0 statistical software (SAS Institute, Cary, NC) was used to 
analyze and determine significance for the ELISA data set. Additionally GraphPad Prism software 
was used to graphically display stratified demographic data.  
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CHAPTER 4 
RESULTS 
 
4.1 Demographics of the Study Population  
 Participants were categorized into 2 BMI based groups: healthy weight (BMI 18.5-25) and 
obese (BMI ≥ 30). Forty-six healthy weight participants and forty-five obese participants were 
found in each group that were HAI negative (N=91). The complete demographics for the study 
population are presented in Table 4. 
  Healthy Weight Obese 
Sample Size  46 45 
BMI Mean ± SE  
Range 
23.3 ± 0.2 
19.5 – 25.4^ 
35.4 ± 0.7 
30 - 46.9 
Age Mean ± SE  
Range 
45.2 ± 1.8 
23 - 60 
47.3 ± 1.6 
20 - 60 
Gender Male 
Female 
19 
27 
17 
28 
Race White 
African-American 
Other 
36 
8 
3 
16 
26 
1 
Table 4. Demographic summary of BMI, age, gender and race in subject population. 
^7 participants’ in the Healthy Weight BMI group had BMI’s of greater than or equal to 25, but 
were kept in the study as healthy weight.  
 
 
 
~ 23 ~ 
 
In addition to the 91 participants selected for this study, two infected patients and two 
pediatric patient serum were also tested for baseline values of antibody against NP, M1 and HA. 
Both pre-vaccination serum samples were from 2 year olds who were HAI negative for pH1N1 
and H3N2, these samples were obtained from the Pediatric Continuity Care Clinic. Two 
convalescent serum samples from individuals who were positive for pH1N1 were obtained from 
BEI resources. One serum sample had a high antibody response, while the other had low antibody 
response; these infected samples were distinguished as Infected Hi and Infected Low. BMI was 
not known for pediatric or infected samples. 
 All participants in the study, excluding the positive control BEI samples, were tested for 
any pre-existing pH1N1 antibodies. This was accomplished by running Hemagglutination 
Inhibition Test (HAI). Figure 1 displays the results of the HAI test for each group of patients, both 
healthy weight and obese. The HAI results clearly show no pre-existing antibodies before 
vaccination, when serum samples were taken and used for purposes of this experiment. In addition, 
there was no significant difference found between the post vaccine antibodies between the healthy 
weight and obese patients.  
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Figure 1. Results of HAI for pre/post-vaccine in healthy weight (HW) and obese patients.  
 
4.2 Convalescent and Pediatric serum antibodies per influenza protein 
 Convalescent and pediatric serum samples were run with the same respective serum 
dilution series as healthy weight and obese for hemagglutinin (HA), matrix protein 1 (M1) and 
nucleoprotein (NP). The pediatric trend lines represents a naïve response to pH1N1 as these 
samples likely do not have any pre-existing antibodies to any influenza strain, and thereby 
functions as a negative control. Additionally the infected trend lines represent a protective level 
against pH1N1, as these samples were exposed to pH1N1 and as a result have developed protective 
antibodies against the influenza strain, and function as a positive control. The O.D values and 
concentrations were logarithmically plotted for graphical interpretation. Figures 2-4 display the 
resulting O.D values vs. concentration for positive and negative controls of each influenza protein. 
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Figure 2. M1 OD values for serial dilution series in infected and pediatric samples. 
 
Figure 3. NP OD values for serial dilution series in infected and pediatric samples. 
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 Figure 4. HA OD values for serial dilution series in infected and pediatric samples. 
  
The infected and pediatric samples gave baseline results for what can be distinguished as 
minimal to no cross-reactive antibody protection, as displayed in the pediatric serum sample trend 
line, and protective antibodies to pH1N1 as displayed by the infected serum samples. The red 
arrow in each respective graph represents the concentration selected for average OD values of 
healthy weight and obese serum samples. These concentrations were selected because the greatest 
difference between infected and pediatric OD values were seen at this level. This dilution has the 
greatest sensitivity to cross reactive antibody response.  These dilutions are specifically 1:750 
(NP), 1:3000 (M1) and 1:27000 (HA). The HA concentration selected was not the first dilution 
because the OD values of the infected Hi patient was at maximal concentration reading, therefore 
a range which had a range above infected Hi was selected. 
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4.3 Healthy Weight and Obese antibody response  
 As mentioned in the section above, the dilutions selected for the study samples were 
determined by the infected and pediatric OD separation. The average M1 antibody OD values at 
dilution factor 1:3000 was calculated for healthy weight and obese patients. Figure 5 below 
displays a graphical representation of this data.  
 
 
Figure 5. M1 mean antibody OD value at a 1:3000 dilution factor. 
 The mean antibody OD value in healthy weight subjects was found to be 1.12 with standard 
error (SE) of 0.13. The mean antibody OD value in obese subjects was found to be 1.01 with SE 
of 0.11. Despite the fact that a greater antibody level was found in healthy weight subjects, the 
difference was not found to be significant between the two groups.  
The mean of OD values at 1:750 for all samples of NP were calculated. Figure 6 below 
shows the bar graph of mean NP OD values in healthy weight and obese subjects. 
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Figure 6. NP mean antibody OD value at a 1:750 dilution factor. 
 The mean antibody OD value in healthy weight subjects was found to be 0.91 with SE of 
0.10. The mean antibody OD value in obese subjects was found to be 0.97 with SE of 0.09. The 
difference between the two groups was not found to be significant.  
 Finally, the mean OD values at 1:27000 for all samples for HA were calculated. Figure 7 
below shows the bar graph of mean HA OD values in healthy weight and obese subjects. 31 lean 
samples and 30 obese samples were used (N=71) for this analysis. Figure 7 displays the bar graph 
of mean +/- SE HA OD values in healthy weight and obese subjects.   
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Figure 7. HA mean antibody OD value at a 1:27000 dilution factor. 
 The mean antibody OD for healthy weight subjects was 1.32 with SE of 0.10. The mean 
antibody OD value for obese patients was 1.28 with a SE of 0.10. The healthy weight subjects did 
have a higher average antibody level than the obese patients, however the difference found 
between antibody levels was not significant. Table 5 below summarizes the OD values for each 
protein conducted in this study.  
 Healthy Weight 
Mean OD ± SE 
Obese 
Mean OD ± SE 
Hemagglutinin (HA) 1.32 ± 0.10 1.28 ± 0.10 
Matrix Protein 1 (M1) 1.12 ± 0.13 1.01 ± 0.11 
Nucleoprotein (NP) 0.91 ± 0.10 0.97 ± 0.09 
Table 5. Mean OD and SE for HA, M1, NP in Healthy Weight and Obese subjects 
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CHAPTER 5 
DISCUSSION 
5.1 Cross Reactive Antibodies to Influenza  
Obesity has recently become a major global health concern as the worldwide population of 
those who are obese has increased to over 1 billion overweight adults. This increase in the rate of 
obesity has resulted in heightened research interest in understanding how obesity contributes to 
wide range of diseases, including type 2 diabetes, cardiovascular disease and cancer.1,7 Of 
particular interest for this thesis project, obesity was recognized as an independent risk factor for 
increased influenza morbidity and mortality during the 2009 influenza pandemic.14 In a typical flu 
season, anywhere from 5% to 20% of US citizens will contract the flu virus.8  
Recent studies suggest that obesity is a risk factor for severity of influenza virus, especially 
during the 2009 pandemic H1N1 outbreak. During the 2009 influenza pandemic, it was found that 
while overall severity to pH1N1 was mild, obese individuals had higher rates of hospitalization 
and death than healthy weight individuals. It was hypothesized that the general decreased severity 
to the pandemic was a result of pre-existing, cross-reactive immunity to the virus. It is known that 
antibodies have the ability to bind to conserved epitopes on different viral antigens, however the 
amount has never been quantified. This is particularly important for the influenza virus, as viral 
antigens change annually; however there are multiple conserved proteins found within the virus. 
It is likely these conserved proteins in the virus will have cross-reactive antibodies that can bind 
and function to increase immune response. Previous vaccination or infection to a certain strain of 
influenza may render protection to different strains of the virus through cross reactive antibodies. 
The purpose of this study was to determine if the impaired immunity seen in obese humans 
stemmed from less pre-existing, non-neutralizing, cross-reactive antibodies.  
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Results from this study show that obese individuals do not have less pre-existing, non-
neutralizing, cross-reactive antibodies than health weight individuals to pH1N1. Although no 
significant differences were found in cross-reacting antibody responses between healthy weight 
and obese subjects, there were some interesting trends identified. The M1 and HA antibody levels 
in healthy weight individuals was higher than that of obese individuals. It is possible with increased 
sample size, the data between the two groups would be significant. 
  
5.2 Limitations 
 There were several limitations in this study. First, the relatively small sample size could 
address the lack of significance found for any of the pandemic protein antibody levels. The sample 
size should be increased with the possibility of finding significance in some of the findings. It is 
possible that with increased sample size the increased antibody levels seen in M1 and HA in 
healthy weight subjects would be significant. It would be ideal to increase the sample size to close 
to 100 in each group, effectively doubling the sample size of the initial study. 
 A recent study demonstrated that perhaps body fat percentage is a better indicator of 
obesity compared with BMI.35 While BMI is a good indicator of relative weight to height and will 
indicate obesity in most patients, it is also possible that individuals with relatively high BMI’s, to 
the extent where they are >30 and considered obese may actually be muscular individuals. Muscle 
mass is 18% more dense than fat.34 This is often why athletes  have high BMI’s but are actually 
very fit and have very little associated obesogenic effects. It is possible that results were skewed 
due to patients being identified as obese, however their BMI was not associated with a large 
amount of fat.  However, this is unlikely, given our study population, as most adults were non-
athletic middle-aged individuals. 
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  Finally, determining OD values based on specific dilution may not have been the correct 
method of approach to determine antibody response against influenza. Individual antibody 
response to an infection may not be determined by a specific OD value, but rather how many 
antibodies the specific individual requires for protection. For means of this study, the greatest 
difference between infected and pediatric serum dilutions was selected; however the OD value 
associated with the healthy weight and obese values may not be representative of their actual 
protection against influenza. Rather than averaging specific OD values for a dilution factor, the 
dilution series should be analyzed to determine when measurable antibody levels stay within 10% 
of the previous dilution factor to determine no longer measurable amounts of antibody.36  
   
5.3 Future studies  
 As mentioned in the limitation section, a titer of the dilution series should be approached 
to determine antibody level to specific proteins of the influenza virus. This will give a more 
justified approach to understanding how obese and healthy weight individuals react to the 
influenza virus. Given the serial dilution series completed for this project, the data could be re-
analyzed to determine if a higher associated titer is found with healthy weight individuals, 
suggesting that despite the initial antibody level is not as high, the antibodies do provide protection 
for the individual and will titer out further than obese subjects.  
 In addition, due to the lack of the significance found for antibody response, it is possible 
that the mechanism for increased susceptibility in obese individuals compared to healthy weight 
individuals to pH1N1 infection does not involve cross-reacting antibodies. Perhaps differences in 
the cellular immune response are more important for protection. Of note, our lab has previously 
demonstrated that obese individuals have impaired CD4+ and CD8+ T cells responses to influenza 
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virus stimulation.   Taken together, our study demonstrated that cross-reacting antibodies could be 
detected in the serum of healthy weight and obese individuals. In addition, we did not detect any 
statistical differences between healthy weight and obese individuals with respect to cross-reacting 
antibody levels. More research is required to understand why obesity puts individuals at greater 
risk for pH1N1 severity. 
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